Carregant...
PI3K Inhibitors: Present and Future
Inhibitors of PI3Kδ hold great potential for the therapy of CLL and B cell malignancies. After initially exciting efficacy results with idelalisib, the first in class inhibitor, the emergence of unexpected and unpredictable autoimmune toxicities, worse in less heavily treated and younger patients, h...
Guardat en:
| Publicat a: | Cancer J |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7082729/ https://ncbi.nlm.nih.gov/pubmed/31764120 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PPO.0000000000000414 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|